Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

Exclusion Criteria

• •Guttate, erythrodermic, or pustular psoriasis.
• •Psoriasis is spontaneously improving.
• •Have had psoriasis that was unresponsive to adequately dosed (\> 10 weeks) cyclosporine.
• •Any systemic disorder or active skin disease (other than psoriasis) or subjects who present with scars, moles, tattoos, body piercings, sunburn in the test area.
• •History of congestive heart failure (NYHA Class 3 or 4), myocardial infarction, coronary artery bypass graft, percutaneous transluminal balloon angioplasty, cerebrovascular accident, chronic or intermittent oedema.
• •Blood pressure of greater than 150mmHg systolic and /or 95mmHg diastolic following triplicate measurements taken 5 minutes apart.
• •Presence of unstable or severe angina or coronary insufficiency.
• •Uncontrolled bacterial, viral, or fungal infection.
• •Congenital or acquired immunodeficiency.
• •History of malignancy within the last five years, except for surgically cured skin carcinoma or cervical dysplasia (CIN I-II).
• •An unwillingness of male subjects to use a condom/spermicide in addition to having their female partner use another form of contraception if the woman could become pregnant from the time of the first dose of study medication until 5 half-lives of the drug have elapsed following removal of the last dose of study medication.
• •An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women from the time of first dose of study medication until five half-lives or 5 days (whichever is longer) following removal of the last dose of study medication.
• •Prolonged exposure to the sun (or tanning beds) during the study.
• •Systemic anti-psoriasis therapy, including but not limited to: acitretin, cyclosporine, isotretinoin, infliximab, entercept, alefacept, oral steroids and psoralen during the 4 weeks prior to the first dose of study medication and throughout the study.
• •Concomitant use of phototherapy or photochemotherapy.
• •Concomitant use of lithium, antimalarials, interferons.
• •Systemic beta-blockers are permitted provided the dose is stable for four weeks before baseline and remains stable throughout the study.
• •Concomitant use of anti-arthritis therapies with known propensity for hepatotoxicity (i.e. diclofenac, gold, D-penicillamine, leflunomide).
• •Use of topical or intralesional treatments for psoriasis (e.g. mid- or high-potency topical corticosteroids) within 2 weeks prior to Day 1 and throughout the study, except for class VI or VII topical steroid treatments (Desonide, or 2.5% hydrocortisone) which will be allowed on the face.
• •Concomitant use of non-drug therapies (i.e. herbal products or alternative therapies) for psoriasis.